#decarbonization #India #Mumbai #Sustainability Report #Piramal Pharma

Piramal Pharma's Commitment to Sustainability

Piramal Pharma Limited (PPL), a recognized name in the global pharmaceutical sector, has recently published its fourth annual Sustainability Report for the financial year 2025, themed 'Innovating Responsibly. Growing Sustainably.' The report elaborates on the company's measurable advancements and reinforced pledges aligned with four strategic pillars: Business Resilience, Quality Excellence, Responsible Operations, and Stakeholder Centricity.

At the heart of Piramal Pharma's operations is a steadfast dedication to ethical practices and sustainable growth characterized by their mantra of 'Doing Well and Doing Good.' The company has demonstrated notable progress in reinforcing governance, advancing climate action, promoting diversity and inclusion, and fostering social impact through collaborative partnerships. Notably, the report has undergone external assurance by DNV, ensuring transparency and accountability.

Business Resilience

The company showcases an emphasis on governance with 50% of its directors being independent, while women hold 30% of board positions, surpassing regulatory requirements. PPL also boasts zero instances of data breaches and full compliance with its Code of Conduct training. There is an ongoing project to assess sustainability criteria for 26.5% of critical suppliers, with a goal to increase this to 30% by FY2026, reflecting their commitment to sustainability throughout the supply chain.

Quality Excellence

The report highlights PPL's unwavering focus on quality, marked by 36 successful regulatory inspections, two of which were conducted by the USFDA. The company has also completed 165 customer audits globally and is furthering digital transformation through initiatives like Catalyst NxGen (S/4HANA). Customer satisfaction levels are commendable, with scores climbing to 85% in CDMO/PPS sectors and 87% in Critical Care/PCC sectors, reflecting their commitment to quality service.

Responsible Operations

A significant section of the report is dedicated to PPL's efforts in responsible operations, particularly in achieving decarbonization milestones. The company has reduced Scope 1 and 2 emissions by 6% year-on-year and increased renewable energy utilization by 7.8%, with 20.2% of total energy sourced from bioenergy. PPL has successfully achieved zero hazardous waste sent to landfills, setting a target to recycle 90% of non-hazardous waste. Moreover, their integrated water stewardship program has saved 210,000 kiloliters of freshwater throughout the fiscal year, underscoring their approach towards resource conservation.

Piral's biodiversity initiatives are equally impressive, with over 2,000 saplings planted and maintaining a green cover of 30% across Indian sites. A notable project involves transitioning their coal-fired steam boiler at the Digwal facility to utilize renewable biomass briquettes, marking a significant leap in their sustainability journey.

Stakeholder Centricity

PPL's commitment to diversity, equity, and inclusion (DEI) is evident, with 30% of its board being women and a 20% female workforce, reflecting a year-on-year increase of 2.7%. Furthermore, 63.3% of campus hires in the past year have been women, demonstrating consistent dedication to building an inclusive workplace culture. The company has also made headway in safety initiatives, achieving a remarkable 45% enhancement in Lost Time Injury Rate (LTIR), thus bringing it down to an impressive 0.05.

Nandini Piramal, Chairperson of Piramal Pharma, encapsulates the ethos of the company: "At Piramal Pharma, sustainability is not just a responsibility — it is a deliberate choice that defines the way we operate and the way we grow. Our commitment to diversity, equity, and inclusion has fostered a more inclusive workplace, while our CSR initiatives have positively impacted over 200 million individuals across various underserved districts. As we continue our sustainability efforts, we aim to create lasting value for our communities, patients, and our shared planet."

In the context of corporate social responsibility (CSR), PPL has made significant investments throughout FY2025, collaborating with the Piramal Foundation across 112 aspirational districts in India. The focus of these initiatives includes enhancing education, community welfare, and empowering women. Highlighting this commitment, the company has allocated ₹5.34 Crores towards programs enhancing school infrastructure, improving teaching capabilities, and addressing health and safe water practices.

PPL has not only engaged its employees in volunteer efforts—ranging from plantation drives to health awareness campaigns—but also partnered with the Life Sciences Sector Skill Development Council to introduce a skill development program led by women near its Digwal facility. The company's ongoing support for the Aspirational Bharat Collaborative (ABC) aims to elevate the lives of 100 million citizens in underserved areas by 2047.

The Sustainability Report adheres to GRI standards and aligns with frameworks like SASSB and UNGC, showcasing PPL's unwavering dedication to sustainable growth, responsible capital allocation, and impactful engagement with stakeholders. For those interested in exploring the full content, the complete report can be accessed here.

About Piramal Pharma Limited

Piramal Pharma Limited operates through its 17 global development and manufacturing facilities, offering a broad portfolio of differentiated products and services across more than 100 countries. The company includes divisions like Piramal Pharma Solutions and Piramal Critical Care, while maintaining strategic investments to enhance its market presence in the pharmaceutical landscape. To learn more about Piramal Pharma, visit their LinkedIn.